1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Pediatric Cancer - Pipeline Review, H2 2013

Pediatric Cancer - Pipeline Review, H2 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 119 pages

Pediatric Cancer - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Pediatric Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pediatric Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pediatric Cancer. Pediatric Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pediatric Cancer.
- A review of the Pediatric Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pediatric Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Pediatric Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pediatric Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Pediatric Cancer - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pediatric Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Pediatric Cancer 9
Pediatric Cancer Therapeutics under Development by Companies 11
Pediatric Cancer Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Pediatric Cancer Therapeutics - Products under Development by Companies 18
Pediatric Cancer Therapeutics - Products under Investigation by Universities/Institutes 19
Companies Involved in Pediatric Cancer Therapeutics Development 20
Boehringer Ingelheim GmbH 20
Shionogi and Co., Ltd. 21
Sanofi-Aventis 22
Antigenics, Inc. 23
Astellas Pharma Inc. 24
Eisai Co., Ltd. 25
SuperGen, Inc. 26
Incyte Corporation 27
AEterna Zentaris Inc. 28
Lixte Biotechnology Holdings, Inc. 29
Marshall Edwards, Inc. 30
Spectrum Pharmaceuticals, Inc. 31
Ambit Biosciences Corporation 32
Crusade Laboratories Limited 33
Stemline Therapeutics, Inc. 34
Innogene Kalbiotech Pte Ltd. 35
PharmaMar, S.A. 36
Polaris Group 37
Pediatric Cancer - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
volasertib - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
firtecan pegol - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
AT-9283 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
decitabine - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
pracinostat - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
ruxolitinib - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
vincristine sulfate - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
racotumomab - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
quizartinib - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
ADI-PEG 20 - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
ADI-PEG 20 - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
erlotinib hydrochloride - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
trabectedin - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
cabazitaxel - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
Seprehvir - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
dactinomycin reformulation - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
etoposide phosphate reformulation - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
vincristine sulfate immunoliposomal - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
methotrexate immunoliposomal - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
Peptide Cocktail Vaccine - Drug Profile 81
Product Description 81
Mechanism of Action 81
RandD Progress 81
Lutetium-177 Dotatate - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
Pediatric Cancer Therapeutics - Drug Profile Updates 83
Pediatric Cancer Therapeutics - Discontinued Products 111
Pediatric Cancer Therapeutics - Dormant Products 112
Pediatric Cancer - Product Development Milestones 113
Featured News and Press Releases 113
Oct 22, 2012: Eleison Enrolls First Patient In Phase II Trial Of Cisplatin For Pediatric Bone Cancer 113
Jul 11, 2012: Scientists Develop New Strategy To Overcome Drug-Resistant Childhood Cancer 113
Feb 24, 2010: Enzon Opens Pediatric Study Of PEG-SN38 114
Jun 01, 2009: Cytokinetics Announces Non-Clinical Data Relating To GSK-923295 Presented At The 2009 Annual Meeting Of The American Society Of Clinical Oncology 114
Oct 23, 2008: Neotropix Announces Presentation Of Preclinical Results Of NTX-010 115
Jun 19, 2007: OSI Pharmaceuticals Begins Clinical Development Program of OSI-906 in Patients with Advanced Solid Tumors 116
Nov 02, 2006: Ziopharm Announces Preclinical Data Of ZIO-201 In Pediatric Cancers 116
Appendix 118
Methodology 118
Coverage 118
Secondary Research 118
Primary Research 118
Expert Panel Validation 118
Contact Us 119
Disclaimer 119



List of Tables

Number of Products Under Development for Pediatric Cancer, H2 2013 9
Products under Development for Pediatric Cancer - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 12
Number of Products under Investigation by Universities/Institutes, H2 2013 13
Comparative Analysis by Late Stage Development, H2 2013 14
Comparative Analysis by Mid Clinical Stage Development, H2 2013 15
Comparative Analysis by Early Clinical Stage Development, H2 2013 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 17
Products under Development by Companies, H2 2013 18
Products under Investigation by Universities/Institutes, H2 2013 19
Boehringer Ingelheim GmbH, H2 2013 20
Shionogi and Co., Ltd., H2 2013 21
Sanofi-Aventis, H2 2013 22
Antigenics, Inc., H2 2013 23
Astellas Pharma Inc., H2 2013 24
Eisai Co., Ltd., H2 2013 25
SuperGen, Inc., H2 2013 26
Incyte Corporation, H2 2013 27
AEterna Zentaris Inc., H2 2013 28
Lixte Biotechnology Holdings, Inc., H2 2013 29
Marshall Edwards, Inc., H2 2013 30
Spectrum Pharmaceuticals, Inc., H2 2013 31
Ambit Biosciences Corporation, H2 2013 32
Crusade Laboratories Limited, H2 2013 33
Stemline Therapeutics, Inc., H2 2013 34
Innogene Kalbiotech Pte Ltd., H2 2013 35
PharmaMar, S.A., H2 2013 36
Polaris Group, H2 2013 37
Assessment by Monotherapy Products, H2 2013 38
Assessment by Stage and Route of Administration, H2 2013 40
Assessment by Stage and Molecule Type, H2 2013 42
Pediatric Cancer Therapeutics - Drug Profile Updates 83
Pediatric Cancer Therapeutics - Discontinued Products 111
Pediatric Cancer Therapeutics - Dormant Products 112



List of Figures

Number of Products under Development for Pediatric Cancer, H2 2013 9
Products under Development for Pediatric Cancer - Comparative Analysis, H2 2013 10
Products under Development by Companies, H2 2013 11
Products under Investigation by Universities/Institutes, H2 2013 13
Late Stage Products, H2 2013 14
Mid Clinical Stage Products, H2 2013 15
Early Clinical Stage Products, H2 2013 16
Discovery and Pre-Clinical Stage Products, H2 2013 17
Assessment by Monotherapy Products, H2 2013 38
Assessment by Route of Administration, H2 2013 39
Assessment by Stage and Route of Administration, H2 2013 40
Assessment by Molecule Type, H2 2013 41
Assessment by Stage and Molecule Type, H2 2013 42



Companies Mentioned

Boehringer Ingelheim GmbH
Shionogi and Co., Ltd.
Sanofi-Aventis
Antigenics, Inc.
Astellas Pharma Inc.
Eisai Co., Ltd.
SuperGen, Inc.
Incyte Corporation
AEterna Zentaris Inc.
Lixte Biotechnology Holdings, Inc.
Marshall Edwards, Inc.
Spectrum Pharmaceuticals, Inc.
Ambit Biosciences Corporation
Crusade Laboratories Limited
Stemline Therapeutics, Inc.
Innogene Kalbiotech Pte Ltd.
PharmaMar, S.A.
Polaris Group

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Lung Cancer: Analytical Tool

August 2016 $ 8096

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.